Tigecycline-induced life-threatening coagulopathy in a patient with a Mycobacterium abscess: a case report and step-by-step diagnostic approach.
Sara AkalayThomas VanasschePaul De MunterPublished in: Acta clinica Belgica (2020)
Tigecycline is a broad-spectrum antibiotic that is indicated in the treatment of complicated intra-abdominal infections and complicated skin and skin and soft-tissue infections. We report the case of a 53-year old kidney transplant patient with a severe Mycobacterium abscess who developed life-threatening coagulopathy after initiation of tigecycline therapy. Further analysis revealed a severe hypofibrinogenemia. A few case reports previously described an association between tigecycline and prolongation of clotting time. Our case confirms an uncommon yet possibly life-threatening side-effect of tigecycline. Medical practitioners should be aware of this potential coagulopathy and we recommend routine monitoring of coagulation parameters in patients receiving tigecycline.
Keyphrases
- acinetobacter baumannii
- klebsiella pneumoniae
- soft tissue
- multidrug resistant
- case report
- drug resistant
- drug induced
- mycobacterium tuberculosis
- pseudomonas aeruginosa
- escherichia coli
- healthcare
- primary care
- early onset
- stem cells
- clinical practice
- high glucose
- wound healing
- cystic fibrosis
- endothelial cells
- diabetic rats